Ribavirin

Respiratory virus infection has long been a common prevention and control demand in the global public health field. As a broad-spectrum nucleoside antiviral drug, ribavirin exerts its effect by inhibiting the activity of viral RNA polymerase and blocking the synthesis of viral nucleic acid, and has inhibitory effects on a variety of pathogens such as respiratory syncytial virus, influenza virus, hepatitis A virus and adenovirus. In clinical practice, it is not only used for the treatment of viral pneumonia and bronchitis caused by respiratory syncytial virus, but also can be used in combination to cope with chronic hepatitis C, epidemic hemorrhagic fever and other diseases. The applicable population covers adults and child patients who meet the medication indications, and it is an important part of the basic antiviral medication matrix.

At present, the global ribavirin market size exceeds 2.2 billion yuan, and the compound annual growth rate remains at around 3.2%. The demand growth is mainly driven by two factors: the popularization of antiviral drugs in primary medical care, and the expansion of prevention and control demand for infectious diseases in emerging markets. The localization rate in the domestic market exceeds 90%, and the winning bid price of batches related to centralized procurement has an average decrease of 67% compared with the highest online listing price, which further promotes the improvement of drug accessibility. Industry competition is concentrated among leading generic pharmaceutical companies. The main production areas of API are concentrated in East China and Central China of China, and the production capacity of leading enterprises accounts for more than 65% of the total supply.

The original developer of ribavirin is ICN Pharmaceuticals, with the original brand name Virazole, and the core compound patent expired in 1985. The main dosage forms of the original product include injection, tablet, aerosol and inhalation solution, and common specifications cover 100mg and 200mg tablets, 1ml:100mg injection, etc. Relevant dosage forms have been included in the FDA Reference Listed Drug Catalog and China's *Catalog of Reference Preparations for Chemical Drugs*. Nearly 60 valid A-status registration numbers can be found on the domestic API registration platform. Both domestic and imported preparations have been approved for marketing in China, covering oral, injection, external use and other administration routes. (Data as of October 2025, please refer to the official website of CDE for the latest information)

CATO provides a full set of ribavirin impurity reference standards, most of which are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. The products fully comply with the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can fully meet the reference standard use needs of pharmaceutical enterprises in different scenarios such as API quality research, consistency evaluation, and quality control in the production process.